The global peptide and oligonucleotide CDMO market size was estimated to be USD 2.61 billion in 2023 and is expected to reach USD 9.64 billion by 2034 with a CAGR of 12.61% during the forecast period 2024-2034. Growing Prevalence of Chronic Diseases and Growing Need for Peptide Therapeutics The market will develop as a result of investments in biopharmaceutical R&D, advancements in oligonucleotide-based therapies, and advancements in manufacturing technology.
Drugs based on oligonucleotides, such as siRNA and antisense oligonucleotides, have showed promise in treating a variety of illnesses and genetic problems. The need for CDMO services that specialize in oligonucleotide synthesis has increased due to the development of novel and more sophisticated oligonucleotide-based medicines. For instance, Bachem Holding AG announced in October 2023 that it was expanding its GMP capacity for bespoke peptides at its plant in Switzerland to meet the increased demand for API synthesis.
By product, the peptides segment accounted for the highest revenue-grossing segment in the global peptide and oligonucleotide CDMO market in 2023 owing to the the pharmaceutical companies segment is predicted to grow at the fastest CAGR during the forecast period owing to the For instance, in December 2023, Lonza Group collaborated with GeneIus therapies to design and produce a cancer treatment cell therapy, utilizing its experience in oligonucleotide therapies. Additionally, the oligonucleotides segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding applications of oligonucleotide-based therapies, such as antisense oligonucleotides and small interfering RNA (siRNA), in the treatment of genetic disorders, rare diseases, and various chronic conditions.
By service type, the contract manufacturing segment accounted for the highest revenue-grossing segment in the global peptide and oligonucleotide CDMO market in 2023 owing to the increasing trend among pharmaceutical and biotechnology companies to outsource manufacturing activities to specialized service providers. For instance, in January 2024, CordenPharma International unveiled a new integrated platform for the synthesis and manufacturing of plasmid DNA with the goal of expediting the development of gene therapy. Additionally, the contract development segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on research and development (R&D) collaborations, a surge in the demand for innovative and customized drug development solutions, and the evolving landscape of peptide and oligonucleotide-based therapies.
By end-user, the biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global peptide and oligonucleotide CDMO market in 2023 owing to the industry's increasing reliance on outsourcing to streamline manufacturing and development processes. For instance, Merck KGaA expanded its peptide production capabilities in China in December 2023 as a result of a strategic alliance with the Shanghai Chemical Research & Development Center. Additionally, the pharmaceutical companies segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating demand for outsourcing services to optimize operational efficiency, reduce costs, and expedite the development and manufacturing of peptide and oligonucleotide-based therapeutics.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established pharmaceutical and biotechnology industries, a robust ecosystem of research and development, and a high prevalence of collaborations and partnerships between industry players and contract development and manufacturing organizations (CDMOs). Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investments in the life sciences sector, expanding biopharmaceutical industry, and a rising focus on research and development activities in countries like China, India, and Japan. For instance, in September 2023, PolyPeptide Group acquired Peptech Therapeutics, granting them access to cutting-edge conjugation technology for the creation of innovative therapeutic peptides.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Drugs based on oligonucleotides, such as siRNA and antisense oligonucleotides, have showed promise in treating a variety of illnesses and genetic problems. The need for CDMO services that specialize in oligonucleotide synthesis has increased due to the development of novel and more sophisticated oligonucleotide-based medicines. For instance, Bachem Holding AG announced in October 2023 that it was expanding its GMP capacity for bespoke peptides at its plant in Switzerland to meet the increased demand for API synthesis.
By product, the peptides segment accounted for the highest revenue-grossing segment in the global peptide and oligonucleotide CDMO market in 2023 owing to the the pharmaceutical companies segment is predicted to grow at the fastest CAGR during the forecast period owing to the For instance, in December 2023, Lonza Group collaborated with GeneIus therapies to design and produce a cancer treatment cell therapy, utilizing its experience in oligonucleotide therapies. Additionally, the oligonucleotides segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding applications of oligonucleotide-based therapies, such as antisense oligonucleotides and small interfering RNA (siRNA), in the treatment of genetic disorders, rare diseases, and various chronic conditions.
By service type, the contract manufacturing segment accounted for the highest revenue-grossing segment in the global peptide and oligonucleotide CDMO market in 2023 owing to the increasing trend among pharmaceutical and biotechnology companies to outsource manufacturing activities to specialized service providers. For instance, in January 2024, CordenPharma International unveiled a new integrated platform for the synthesis and manufacturing of plasmid DNA with the goal of expediting the development of gene therapy. Additionally, the contract development segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on research and development (R&D) collaborations, a surge in the demand for innovative and customized drug development solutions, and the evolving landscape of peptide and oligonucleotide-based therapies.
By end-user, the biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global peptide and oligonucleotide CDMO market in 2023 owing to the industry's increasing reliance on outsourcing to streamline manufacturing and development processes. For instance, Merck KGaA expanded its peptide production capabilities in China in December 2023 as a result of a strategic alliance with the Shanghai Chemical Research & Development Center. Additionally, the pharmaceutical companies segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating demand for outsourcing services to optimize operational efficiency, reduce costs, and expedite the development and manufacturing of peptide and oligonucleotide-based therapeutics.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established pharmaceutical and biotechnology industries, a robust ecosystem of research and development, and a high prevalence of collaborations and partnerships between industry players and contract development and manufacturing organizations (CDMOs). Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investments in the life sciences sector, expanding biopharmaceutical industry, and a rising focus on research and development activities in countries like China, India, and Japan. For instance, in September 2023, PolyPeptide Group acquired Peptech Therapeutics, granting them access to cutting-edge conjugation technology for the creation of innovative therapeutic peptides.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Service Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Peptide and Oligonucleotide CDMO Market Report 2023 - 2034
Peptide and Oligonucleotide CDMO Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Peptides
- Oligonucleotides
Peptide and Oligonucleotide CDMO Market Analysis & Forecast by Service Type 2023 - 2034 (Revenue USD Bn)
- Contract Development
- Contract Manufacturing
Peptide and Oligonucleotide CDMO Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Others
Peptide and Oligonucleotide CDMO Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis
8. Peptide and Oligonucleotide CDMO Market: Service Type Estimates & Trend Analysis
9. Peptide and Oligonucleotide CDMO Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Peptide and Oligonucleotide CDMO Market
12. Europe Global Peptide and Oligonucleotide CDMO Market
13. Asia Pacific Global Peptide and Oligonucleotide CDMO Market
14. Latin America Global Peptide and Oligonucleotide CDMO Market
15. MEA Global Peptide and Oligonucleotide CDMO Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Bachem Holding AG
- Lonza Group
- CordenPharma International
- Merck KGaA (MilliporeSigma)
- PolyPeptide Group
- Symbiotec Pharmalab
- KBI Biopharma
- Genscript Biotech Corporation
- Biosynthesis Inc.
- Protagen Protein Services GmbH
- Asymchem Laboratories
- PeptiDream Inc.
- Avid Bioservices
- Sarepta Therapeutics
- Ajinomoto Bio-Pharma Services.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.61 Billion |
| Forecasted Market Value ( USD | $ 9.64 Billion |
| Compound Annual Growth Rate | 12.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
